Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Telesis Bio Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Telesis Bio Reports Second Quarter 2023 Financial Results -- Total revenue of $8.7M in 2QFY23 - increased by 53% year over year"
07/07/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/09/2023 8-K Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Departure of Directors or Cert...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Certificate of Designation of Redeemable Convertible Preferred Stock",
"Form of Warrant issued to an affiliate of H.C. Wainwright & Co., LLC",
"Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock"
05/31/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Form of Certificate of Designation of Redeemable Convertible Preferred Stock",
"Form of Short-Term Warrant",
"Form of Long-Term Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Redeemable Convertible Preferred Stock and Warrant Purchase Agreement",
"Form of Registration Rights Agreement",
"Amendment to Investors’ Rights Agreement",
"Telesis Bio Secures Financing of $28.0 Million Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from NorthPond Ventures, M-185 Corporation and BroadOak Capital Partners"
05/11/2023 8-K Quarterly results
Docs: "Telesis Bio Reports First Quarter 2023 Financial Results -- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28%"
03/21/2023 8-K Quarterly results
Docs: "Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance -- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21 -- BioXp® Revenue increased by 158% to $3.4M, in 4QFY22 over 4QFY21"
01/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Vice President of Investor Relations"
11/08/2022 8-K Quarterly results
Docs: "Vice President of Finance"
10/28/2022 8-K Quarterly results
07/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/24/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/22/2022 8-K Quarterly results
12/29/2021 8-K Quarterly results
11/22/2021 8-K Other Events  Interactive Data
11/10/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "EX-10.1#"
09/16/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
07/20/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy